IL133962A0 - Combination therapy comprising atorvastatin and an antihypertensive agent - Google Patents

Combination therapy comprising atorvastatin and an antihypertensive agent

Info

Publication number
IL133962A0
IL133962A0 IL13396298A IL13396298A IL133962A0 IL 133962 A0 IL133962 A0 IL 133962A0 IL 13396298 A IL13396298 A IL 13396298A IL 13396298 A IL13396298 A IL 13396298A IL 133962 A0 IL133962 A0 IL 133962A0
Authority
IL
Israel
Prior art keywords
atorvastatin
combination therapy
antihypertensive agent
antihypertensive
agent
Prior art date
Application number
IL13396298A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL133962A0 publication Critical patent/IL133962A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Pyrrole Compounds (AREA)
IL13396298A 1997-08-29 1998-08-11 Combination therapy comprising atorvastatin and an antihypertensive agent IL133962A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29
PCT/IB1998/001230 WO1999011260A1 (en) 1997-08-29 1998-08-11 Combination therapy comprising atorvastatin and an antihypertensive agent

Publications (1)

Publication Number Publication Date
IL133962A0 true IL133962A0 (en) 2001-04-30

Family

ID=22009602

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13396298A IL133962A0 (en) 1997-08-29 1998-08-11 Combination therapy comprising atorvastatin and an antihypertensive agent
IL133962A IL133962A (en) 1997-08-29 2000-01-09 A pharmaceutical preparation that includes atorostatin and an alpha-adrenergic or diuretic receptor blocker

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133962A IL133962A (en) 1997-08-29 2000-01-09 A pharmaceutical preparation that includes atorostatin and an alpha-adrenergic or diuretic receptor blocker

Country Status (41)

Country Link
US (2) US20020099046A1 (bg)
EP (1) EP1009400B1 (bg)
JP (2) JP2001514223A (bg)
KR (3) KR20040106591A (bg)
CN (3) CN1473566A (bg)
AP (1) AP1191A (bg)
AR (1) AR016399A1 (bg)
AT (1) ATE285767T1 (bg)
AU (1) AU740424B2 (bg)
BG (1) BG64724B1 (bg)
BR (1) BR9811556A (bg)
CA (1) CA2296723A1 (bg)
CO (1) CO4970724A1 (bg)
DE (1) DE69828413T2 (bg)
DZ (1) DZ2595A1 (bg)
EA (1) EA200000012A1 (bg)
EG (1) EG24678A (bg)
ES (1) ES2234134T3 (bg)
GT (1) GT199800126A (bg)
HR (1) HRP980474A2 (bg)
HU (1) HUP0004318A3 (bg)
ID (1) ID24118A (bg)
IL (2) IL133962A0 (bg)
IS (1) IS5341A (bg)
MA (1) MA26536A1 (bg)
MY (1) MY121008A (bg)
NO (1) NO323987B1 (bg)
NZ (2) NZ530630A (bg)
OA (1) OA11291A (bg)
PA (1) PA8457901A1 (bg)
PE (1) PE107099A1 (bg)
PL (1) PL339091A1 (bg)
PT (1) PT1009400E (bg)
SA (1) SA98190603B1 (bg)
SK (1) SK1432000A3 (bg)
TN (1) TNSN98155A1 (bg)
TR (1) TR200000563T2 (bg)
UY (1) UY25155A1 (bg)
WO (1) WO1999011260A1 (bg)
YU (1) YU2000A (bg)
ZA (1) ZA987839B (bg)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999047138A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1218017B1 (en) 1999-09-24 2005-11-16 Vasogen Ireland Limited Combination of a statin and ex-vivo treated blood for treating atherosclerosis
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
RU2275363C2 (ru) 2000-07-19 2006-04-27 Новартис Аг Соли валсартана, фармацевтическая композиция на их основе и способ получения солей
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
CA2452678A1 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Combination of eplerenone and an hmg coa reductase inhibitor
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20040039055A1 (en) * 2002-06-20 2004-02-26 Lopaschuk Gary D. Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
KR101468827B1 (ko) * 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
BRPI0607142A2 (pt) * 2005-02-17 2009-08-11 Chiesi Farma Spa combinações terapêuticas de manidipina e uma estatina, seu uso e um kit
WO2007111027A1 (ja) 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
JP5377317B2 (ja) * 2006-10-30 2013-12-25 ハナル バイオファーマ カンパニー リミテッド 放出性が制御されたアンジオテンシン−ＩＩ−受容体遮断剤とＨＭＧ−ＣｏＡ還元酵素阻害剤の複合組成物
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
JP5658172B2 (ja) * 2009-01-23 2015-01-21 ハンミ・サイエンス・カンパニー・リミテッド アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
EA201790905A1 (ru) 2014-10-23 2017-09-29 Арена Фармасьютикалз, Инк. Способ лечения состояний, связанных с рецептором pgi2
WO2017003186A1 (en) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
EP3463322A4 (en) * 2016-06-02 2019-11-20 Ana Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERCALCIURY AND NEPHRITICAL CALCULATION
RU2019126749A (ru) 2017-01-25 2021-02-26 Зэ Джордж Инститьют Фор Глобал Хелс Композиции для лечения гипертензии
AU2018227842B2 (en) 2017-03-01 2024-05-02 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CA3107616A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
ATE348607T1 (de) * 1995-11-02 2007-01-15 Warner Lambert Co Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration

Also Published As

Publication number Publication date
MY121008A (en) 2005-12-30
HUP0004318A3 (en) 2002-10-28
NO20000996L (no) 2000-04-27
BG104075A (bg) 2000-09-29
JP2001514223A (ja) 2001-09-11
AR016399A1 (es) 2001-07-04
PA8457901A1 (es) 2000-05-24
OA11291A (en) 2003-08-25
YU2000A (sh) 2002-12-10
PE107099A1 (es) 1999-11-06
ID24118A (id) 2000-07-06
EP1009400B1 (en) 2004-12-29
NO323987B1 (no) 2007-07-30
NZ502280A (en) 2002-11-26
US20030199492A1 (en) 2003-10-23
JP2005041875A (ja) 2005-02-17
NZ530630A (en) 2005-05-27
CN1473567A (zh) 2004-02-11
PT1009400E (pt) 2005-02-28
US20020099046A1 (en) 2002-07-25
AU8458998A (en) 1999-03-22
KR20040106591A (ko) 2004-12-17
AU740424B2 (en) 2001-11-01
BR9811556A (pt) 2000-08-22
EG24678A (en) 2010-04-27
HRP980474A2 (en) 1999-06-30
WO1999011260A1 (en) 1999-03-11
ZA987839B (en) 2000-02-28
DE69828413D1 (de) 2005-02-03
MA26536A1 (fr) 2004-12-20
AP1191A (en) 2003-07-19
AP9801332A0 (en) 1998-09-30
SK1432000A3 (en) 2000-12-11
HUP0004318A2 (hu) 2001-05-28
GT199800126A (es) 2000-01-29
ES2234134T3 (es) 2005-06-16
UY25155A1 (es) 2000-12-29
KR20030015394A (ko) 2003-02-20
DE69828413T2 (de) 2005-12-08
TR200000563T2 (tr) 2000-07-21
EA200000012A1 (ru) 2000-08-28
DZ2595A1 (fr) 2003-02-22
CN1268053A (zh) 2000-09-27
BG64724B1 (bg) 2006-01-31
CN1473566A (zh) 2004-02-11
TNSN98155A1 (fr) 2005-03-15
NO20000996D0 (no) 2000-02-28
IS5341A (is) 2000-01-14
PL339091A1 (en) 2000-12-04
KR20010022477A (ko) 2001-03-15
IL133962A (en) 2006-07-05
EP1009400A1 (en) 2000-06-21
SA98190603B1 (ar) 2006-07-04
CO4970724A1 (es) 2000-11-07
ATE285767T1 (de) 2005-01-15
CA2296723A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
IL133962A0 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
SI1491193T1 (sl) Terapevtske kombinacije, ki vsebujejo amlodipin in atorvastatin
EP1047426A4 (en) USE OF METHYLNALTREXONE AND RELATED COMPOUNDS
AP9801175A0 (en) Quinoline and quinoline compounds useful in therapy
ZA989993B (en) Sterilization wrap and procedures
IL127306A0 (en) Combination therapy
GB9702354D0 (en) Compounds and their use
GB9712761D0 (en) Quinolines and their therapeutic use
HUP9800146A3 (en) Thalidomide-derivatives and use of them
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
IL123535A0 (en) Benzoxazindione derivatives and their use
ZA986047B (en) 6-pyrrolidin-2-ylpyrindines their preparation and their therapeutic application
SI1009400T1 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
EP0998578A4 (en) SEL-10 AND USES OF SEL-10
PL341293A1 (en) Beta-lypothropin and application thereof
EP1112250A4 (en) THERAPEUTIC COMPOUNDS AND RELATED METHODS
ZA988065B (en) Pyrimidin-2-oxy-4-one and pyrimidin-2-oxy-4-thione derivatives
GB9722392D0 (en) Composition and use
EP1150967A4 (en) THERAPEUTICALLY APPLICABLE CONNECTIONS AND METHODS
EP1030608A4 (en) SURGICAL SAW AND RELATED METHODS
GB9720258D0 (en) Extravise and Inavise
GB9704350D0 (en) Compounds and their therapeutic use
GB9708155D0 (en) Add and see
GB2321203B (en) Gaming-table and barrier therefor
GB9714298D0 (en) Quinolines and their therapeutic use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees